Press Releases Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
2.41 ^USD	-1.09%		-5.49%	-60.81%

Feb. 27	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Feb. 27	Top Midday Decliners	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	Feb. 27	AQ
Minerva Neurosciences: Q4 Earnings Snapshot	Feb. 22	AQ
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates	Feb. 22	AQ
Minerva Neurosciences: Q3 Earnings Snapshot	Nov. 07	AQ
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates	Nov. 07	AQ
Minerva Neurosciences : Aug 15, 2023	23-08-15	PU
Minerva Neurosciences: Q2 Earnings Snapshot	23-08-01	AQ
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates	23-08-01	AQ
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market	23-06-28	AQ
MINERVA NEUROSCIENCES, INC. : Other Events (form 8-K)	23-06-20	AQ
MINERVA NEUROSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-06-02	AQ
Minerva Neurosciences: Q1 Earnings Snapshot	23-05-15	AQ
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates	23-05-15	AQ
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia	23-05-10	AQ
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023	23-05-08	AQ
MINERVA NEUROSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)	23-05-05	AQ
MINERVA NEUROSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	23-05-01	AQ
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia	23-05-01	AQ
Minerva Neurosciences: Q4 Earnings Snapshot	23-03-08	AQ
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates	23-03-08	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Press Releases

Filters